SCHEMBL20115746

SCHEMBL20115746

CSc1cncc(CC(C)c2ccccn2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PCSK9 Q8NBP7 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ CHRM2 P08172 1/20 0.36
▸ CHRM4 P08173 1/20 0.36
▸ CHRM5 P08912 1/20 0.36
▸ CHRM1 P11229 1/20 0.36
▸ CHRM3 P20309 1/20 0.36
▸ TSHR P16473 2/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ ESR1 P03372 1/20 0.35
▸ ESR2 Q92731 1/20 0.35
▸ CYP1A2 P05177 2/20 0.34
▸ CYP3A4 P08684 2/20 0.34
▸ KCNA5 P22460 4/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23661902 0.82 CYP11B1 (0.44) TSHRESR1ESR2CYP1A2CYP3A4
SCHEMBL18427303 0.82 KCNA5 (0.39) MEN1ALDH1A1KMT2ASMN1; SMN2CHRM2
SCHEMBL18598771 0.81 KCNH2 (0.37) CHRM2CHRM1TSHRESR1ESR2
SCHEMBL18811782 0.81 ESR1 (0.37) ALDH1A1SMN1; SMN2CHRM2TSHRESR1
SCHEMBL21012176 0.78 CYP1A2 (0.39) MEN1ALDH1A1KMT2ATSHRESR1
SCHEMBL21675851 0.76 SLC6A4 (0.31) ESR1ESR2MAOASLC6A2SLC6A4
SCHEMBL22426189 0.75 CYP1A2 (0.37) ALDH1A1CHRM2CHRM4CHRM5CHRM1
SCHEMBL3249970 0.74 MAOA (0.50) ALDH1A1MAPTSMN1; SMN2CHRM2TSHR
SCHEMBL21085218 0.72 ALDH1A1 (0.33) ALDH1A1SMN1; SMN2TSHRNPC1ESR1
SCHEMBL25003875 0.70 TSHR (0.41) MEN1KMT2ASMN1; SMN2CHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10308617-B2 Triazole benzamide derivatives and the compositions and methods of treatment regarding the same An2H Discovery Limited (IE) 2019-06-04 — — US disclosed
US-20180118697-A1 TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME NYSNOBIO IRELAND DAC (IE) 2018-05-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180118697-A1 TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME PINK1, ATG7, ADRM1 PCSK9 4304/4885MEN1 3909/4885ALDH1A1 504/4885
US-10308617-B2 Triazole benzamide derivatives and the compositions and methods of treatment regarding the same PINK1, ATG7, ADRM1 PCSK9 4304/4885MEN1 3909/4885ALDH1A1 504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback